Mediaspace scheduled maintenance: Aug 25, 2026 07:00 - 12:00 AM. During this time, videos will be temporarily unavailable. Check status updates.

Recherche

Afficher tous les résultats pour

Accueil

Personne

Elizabeth Anne Allen

Cette personne a quitté l’EPFL

À propos
Confidentialité
Mentions légales

Graph Chatbot

Publications associées (4)

Page 1 sur 1

A new effLuc/Kate dual reporter allele for tumor imaging in mice

Douglas Hanahan, Mélanie Louise Tichet, Ke Cheng, Elizabeth Anne Allen

Genetically engineered mouse models (GEMMs) are instrumental for modelling local and systemic features of complex diseases, such as cancer. Non-invasive, longitudinal cell detection and monitoring in tumors, metastases and/or the micro-environment is param ...

The Company of Biologists2025

Nkx2.1-derived astrocytes and neurons together with Slit2 are indispensable for anterior commissure formation

Elizabeth Anne Allen

Guidepost cells present at and surrounding the midline provide guidance cues that orient the growing axons through commissures. Here we show that the transcription factor Nkx2.1 known to control the specification of GABAergic interneurons also regulates th ...

Nature Publishing Group2015

Consensus guidelines for the use and interpretation of angiogenesis assays

Michele De Palma, Patrycja Nowak-Sliwinska, George Coukos, Elizabeth Anne Allen

The formation of new blood vessels, or angiogenesis, is a complex process that plays important roles in growth and development, tissue and organ regeneration, as well as numerous pathological conditions. Angiogenesis undergoes multiple discrete steps that ...

2018

Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition

Douglas Hanahan, Elizabeth Anne Allen

Purpose: Preclinical trials of a mouse model of pancreatic neuroendocrine tumors (PNET) were conducted to determine whether dual FGF/VEGF pathway inhibition with brivanib can improve first-line efficacy in comparison with VEGF inhibitors lacking fibroblast ...

American Association for Cancer Research2011